leisure time -WSS

leisure time

author：fashion 2025-09-27 10:00:39 - browse：52974

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Medicare threatens to cut off funding for HCA's Mission hospital

WSS

Key House Republican on health care plans exit from Congress

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

Biden warns of ‘dark winter’ during final presidental debate

BioAge raises $170M for combination therapy with Zepbound

Medical mystery: When a cough is not just a cough

Why patients can’t get everything they want on drug pricing

entertainment

leisure time

entertainment

Novavax promises a turnaround & Lilly roils the obesity market

To avoid data mishandling cases, universities eye AI and other tools

Heart attack and stroke risk calculators need revising

Truvian presents data for its desktop blood

Jerome Adams on the need for new antivirals for Covid

How digital tools helped lower hypertension in marginalized patients

Psychedelics group wrestles with new pharma identity

CDC Director Mandy Cohen on transparency, trust, and health

Hepatitis C has a cure — but many Americans still lack access to it

The battle over 'scope creep' and who gets to be called 'doctor'

hotspot

What to watch for from Zogenix and Amicus clinical trials

What causes rare myocarditis in young men after Covid vaccines?

What should King Charles tell the public about his cancer?

What to watch for from Zogenix and Amicus clinical trials

PhRMA lawsuit over Medicare drug price negotiation tossed

Biogen Alzheimer’s drug launch off to slow start

knowledge

knowledge

leisure time

Wikipedia